GSK Eyes AnaptysBio Acquisition to Secure Drug Control

British pharmaceutical giant GSK is in talks to acquire AnaptysBio, a biotechnology company specializing in immunology. This move would enable GSK to fully take control of drug candidates developed by AnaptysBio under existing partnership agreements. According to sources, although the deal is not yet finalized, the parties are expected to reach an agreement soon. AnaptysBio is known for developing antibody-based therapies, particularly for the treatment of autoimmune diseases. Among the company's prominent candidates is a drug co-developed with GSK that shows promise in conditions such as rheumatoid arthritis. Through this acquisition, GSK aims to fully integrate the commercial rights and future revenue potential of this drug into its own portfolio. Experts note that this acquisition would strengthen GSK's immunology portfolio and reduce risks in the company's R&D pipeline. While no official valuation figure has been disclosed for AnaptysBio, market analysts estimate the deal could be worth billions of dollars. GSK's move is seen as part of a broader strategy among large pharmaceutical companies to internalize externally sourced innovation. If the deal is completed, GSK is expected to acquire all shares of AnaptysBio and delist the company from the stock exchange. This process will be subject to regulatory approvals and shareholder consent. While no official statement has been made by GSK yet, developments are being closely monitored. This is not investment advice.